Chinese experts have found that biomarkers of Alzheimer's disease can be predicted five to seven years in advance.

Jia Jianping said there is no effective drug to cure Alzheimer's disease, and several Alzheimer's drugs have failed in clinical trials, possibly because the subjects are at a late stage of their illness.
"If a patient is intervened in the early stages of Alzheimer's disease or even during the asymptomatic period, clinical symptoms may be delayed, so it is critical that accurate diagnosis can be made in the early stages of Alzheimer's disease or even asymptomatic stages, which is a new way of thinking for the prevention and treatment of Alzheimer's disease today."
, " said Professor Jia Jianping.
learned that the team collected 739 subjects from people with normal cognitive function five to seven years ago and found and validated exosome synactin as a biomarker for predicting Alzheimer's disease and mild cognitive impairment 5 to 7 years before the onset of cognitive impairment.
the study was further validated by subjects in the familial Alzheimer's cohort, suggesting that tests related to the biomarkers above could predict Alzheimer's disease five to seven years in advance.
The effective diagnosis of the early or asymptomatic stage of Alzheimer's disease can gain time in its ultra-early intervention, thereby increasing the effectiveness of treatment and reducing the incidence of the disease," said Jia Jianping, a doctor.
" The study, "Exosome Neurogenic Exosynol Predicts Asymptomatic Periods of Alzheimer's Disease," was published online August 10, 2020 in the international medical journal Alzheimer's disease and Alzheimer's.
.